Effects of Rosiglitazone on the Diabetic Heart
Author Information
Author(s): Wilson Kitchener D., Li Zongjin, Wagner Roger, Yue Patrick, Tsao Phillip, Nestorova Gergana, Huang Mei, Hirschberg David L., Yock Paul G., Quertermous Thomas, Wu Joseph C.
Primary Institution: Stanford University School of Medicine
Hypothesis
What are the effects of rosiglitazone on cardiac gene expression in a diabetic mouse model?
Conclusion
Rosiglitazone treatment did not significantly reverse the altered gene expression patterns in the diabetic heart.
Supporting Evidence
- The db/db gene expression signature was markedly different from control.
- Rosiglitazone treatment did not significantly reverse the altered gene expression patterns.
- Several genes related to cardiac function were upregulated in response to rosiglitazone.
Takeaway
This study looked at how a diabetes drug called rosiglitazone affects the hearts of mice with diabetes, and found that it doesn't fix the problems caused by diabetes.
Methodology
The study involved cardiac gene expression profiling and imaging studies in db/db mice treated with rosiglitazone compared to untreated and control mice.
Potential Biases
Potential bias in the interpretation of gene expression data and the effects of treatment.
Limitations
The study was conducted in a murine model, which may not fully replicate human responses.
Participant Demographics
C57BL/KLS-leprdb/leprdb (db/db) mice were used as the diabetic model.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website